SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing the next generation of oncology therapeutics, today announced that Goldman Sachs (NYSE:GS) is recognizing Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo, as one of the Most Exceptional Entrepreneurs of 2024 at its Builders and Innovators Summit in Healdsburg, California..

圣地亚哥--（商业新闻短讯）--Avenzo Therapeutics，Inc.（“Avenzo”）是一家开发下一代肿瘤治疗药物的临床阶段生物技术公司，今天宣布，高盛（纽约证券交易所：GS）在加利福尼亚州希尔德斯堡的建筑商和创新者峰会上，认可Avenzo联合创始人、总裁兼首席执行官雅典娜·Countouriotis医学博士为2024年最杰出的企业家之一。。

Goldman Sachs selected Dr. Countouriotis from multiple industries to be honored at the two-day event. Dr. Countouriotis co-founded Avenzo in 2022 after leading Turning Point Therapeutics as President and Chief Executive Officer through its IPO in 2019 to its eventual acquisition by Bristol Myers Squibb for $4.1 billion in August 2022.

高盛选择了来自多个行业的Countouriotis博士参加为期两天的活动。Countouriotis博士于2022年共同创立了Avenzo，此前他在2019年首次公开募股（IPO）中领导转折点治疗公司（Turning Point Therapeutics）担任总裁兼首席执行官，最终于2022年8月以41亿美元被百时美施贵宝（Bristol-Myers Squibb）收购。

With over 20 years of industry experience, she has served as an officer in both public and private companies, led multiple initial public offerings and acquisitions, and guided several development programs to approval in the U.S. and Europe..

凭借20多年的行业经验，她曾在上市公司和私营公司担任高管，领导了多次首次公开募股和收购，并指导了多项发展计划在美国和欧洲获得批准。。

“It is a great honor to be recognized by Goldman Sachs among such a distinguished group of entrepreneurs,” said Athena Countouriotis, M.D., Co-founder, President and CEO of Avenzo Therapeutics. “This recognition is a reflection of the commitment and tireless efforts of our team at Avenzo, as we work to advance our pipeline of next-generation oncology therapies to potentially transform cancer treatment for patients.”.

Avenzo Therapeutics联合创始人、总裁兼首席执行官Athena Countouriotis医学博士表示：“能够在如此杰出的企业家群体中获得高盛的认可，我感到非常荣幸。”。“这一认可反映了我们Avenzo团队的承诺和不懈努力，因为我们正在努力推进下一代肿瘤治疗的管道，以潜在地改变患者的癌症治疗。”。

“I am thrilled to recognize Athena Countouriotis, M.D. as one of the most exceptional entrepreneurs of 2024,” said David Solomon, Chairman and CEO of Goldman Sachs. “Athena and her team have built an impressive business that continues to grow at scale. We look forward to bringing this year’s cohort together to share insights on topics ranging from the evolving geopolitical landscape and accessing new pools of capital to using the power of storytelling to reach new audiences.”.

高盛董事长兼首席执行官大卫·所罗门（DavidSolomon）表示：“我很高兴认识到医学博士雅典娜·Countouriotis是2024年最杰出的企业家之一。”。“雅典娜和她的团队已经建立了一个令人印象深刻的业务，并在规模上不断增长。我们期待着将今年的团队聚集在一起，分享关于不断变化的地缘政治格局、获取新资金池以及利用讲故事的力量吸引新观众等主题的见解。”。

In its 13th year, Goldman’s Builders and Innovators Summit is the can’t miss gathering for Founders and CEOs of high growth companies. Previous honorees have gone on to lead multi-billion dollar companies, both in the private and public markets. In addition to honoring the most exceptional entrepreneurs each year, the Summit consists of general sessions and clinics led by seasoned entrepreneurs, academics and business leaders as well as resident scholars..

高盛建设者和创新者峰会（Goldman's Builders and Innovators Summit）已举办了13年，是高增长公司创始人和首席执行官不容错过的聚会。之前的获奖者曾在私人和公共市场领导数十亿美元的公司。除了每年表彰最杰出的企业家外，峰会还包括由经验丰富的企业家、学者、商界领袖以及常驻学者领导的普通会议和诊所。。

About Avenzo Therapeutics

关于Avenzo Therapeutics

Avenzo Therapeutics is a clinical-stage biotechnology company focused on developing the next generation of oncology therapies for patients. The company’s lead drug candidate, AVZO-021, is a novel, highly potent and selective inhibitor of CDK2, a key enzyme involved in cell cycle regulation. AVZO-021 is being studied in a Phase 1 study in the U.S.

Avenzo Therapeutics是一家临床阶段生物技术公司，专注于为患者开发下一代肿瘤疗法。该公司的主要候选药物AVZO-021是一种新型，高效和选择性的CDK2抑制剂，CDK2是参与细胞周期调控的关键酶。AVZO-021正在美国进行第一阶段研究。

for the treatment of advanced solid tumors and in combinations in HR+/HER2-negative metastatic breast cancer. Avenzo is headquartered in San Diego, California. For more information, visit us at www.avenzotx.com or on LinkedIn..

用于治疗晚期实体瘤以及HR+/HER2阴性转移性乳腺癌的组合。Avenzo总部位于加利福尼亚州圣地亚哥。有关更多信息，请访问www.avenzotx.com或LinkedIn。。

About Goldman Sachs

关于高盛

Goldman Sachs is a leading global financial institution that delivers a broad range of financial services to a large and diversified client base that includes corporations, financial institutions, governments and individuals. Founded in 1869, the firm is headquartered in New York and maintains offices in all major financial centers around the world..

高盛是一家领先的全球金融机构，为包括公司、金融机构、政府和个人在内的大型多元化客户群提供广泛的金融服务。该公司成立于1869年，总部位于纽约，在全球所有主要金融中心设有办事处。。

Press related questions about the Summit or Goldman Sachs, please contact Sophia Anthony at Sophia.Anthony@gs.com.

有关峰会或高盛的新闻相关问题，请联系Sophia AnthonySophia.Anthony@gs.com.